PROCEDURE FOR OBTAINING AND CONSERVING HIGH PURITY GROWTH FACTORS AND THEIR USES (Machine-translatio

专利摘要:
The present invention refers to a process for obtaining and preserving high purity growth factors (with a concentration greater than 90%). The procedure comprises the stages of activating a plasma rich in growth factors, incubation, cooling, extraction of growth factors with a concentration greater than 90% and deep-freezing. The growth factors obtained by the process of the present invention are used in tissue bioregeneration treatments. (Machine-translation by Google Translate, not legally binding)
公开号:ES2782723A1
申请号:ES201930230
申请日:2019-03-13
公开日:2020-09-15
发明作者:Moron Juan Carlos Serrano
申请人:Active Bioregeneration Tech Sl；
IPC主号:

专利说明:

[0004] TECHNICAL SECTOR
[0006] The present invention relates to a process for obtaining and conserving high purity growth factors (greater than 90%) applicable in clinical bioregeneration treatments, particularly in stomatology, dentistry, aesthetics, traumatology, dermatology and rheumatology.
[0008] BACKGROUND OF THE INVENTION
[0010] Platelets (PLT), commonly known for their role in the coagulation process, are cells that do not have a nucleus and therefore lack cell division properties. These cytoplasmic fragments from the megakaryocyte division contain three types of granules inside: dense granules, lysosomal and alpha granules. Alpha granules are of great interest since inside they house the so-called growth factors (FC) that have various tissue repair functions and marked angiogenic activity. Thus, there is the beta transforming FC, the epidermal or epithelial growth FC, the vascular endothelial FC (angiogenic), the acid-base fibroblast FC and the IGF I insulin type, among others.
[0012] The FCs released by alpha granules have been shown to be effective in inducing tissue and functional regeneration in tissues with affected or underactive cells. For example, if a fibroblast in the skin has stopped producing collagen, an injection of autologous FC in the area to be treated provides an inducing factor on the fibroblast (or target cell), resulting in the 'new' production of collagen from the fibroblast. affected.
[0014] Therefore, plasma rich in activated growth factors (PRGF, Plasma Rich Growth Factor) is of great scientific interest. Its procedure for obtaining it goes beyond carrying out a blood extraction and centrifuging it to separate the fraction richest in platelets. Platelets alone do not have regenerative action, but must be activated in order for the alpha granules to release FC.
[0015] Procedures for obtaining PRP are widely described in the state of the art. For example, document ES2567603T3 discloses a method that makes it possible to generate a PRP concentrate, and that comprises the separation from a sample of whole blood mixed with anticoagulants of a fraction of plasma poor in platelets and of another rich in platelets by means of centrifugation. The method further includes platelet count determination of platelet concentration after separation, and a procedure comprising mixing platelet-rich volumes with platelet-poor volumes so that a desired minimum concentration of 800,000 to 2,000,000 is achieved. platelets / ^ l in all fractions.
[0017] Also, document WO2014126931A describes the obtaining of PRP for cosmetic (aesthetic) or therapeutic uses in the field of traumatology and rheumatology. The production process comprises the use of calcium chloride as an activator and inducer of gel formation from PRP. Furthermore, reference is made to the possibility of cryo-preserving the material obtained at temperatures below -20 ° C by known procedures for the preservation of cells.
[0019] On the other hand, some procedures for PRP activation and the biological and medical utilities of the product are also described. Examples of this can be found in document ES2527967A2, which indicates the use of sodium gluconate as an activator of platelet rich plasma.
[0021] In particular, moreover, a publication entitled "Platelet-rich plasma" 1 describes a procedure for obtaining PRP and its activation for application in dentistry. This document describes the steps of extraction of the blood sample and deposit in containers, addition of 3.2% sodium citrate as an anticoagulant, centrifugation and addition of 10% calcium chloride or calcium gluconate as platelet activator to obtain growth factors to be used in dentistry.
[0023] Although several procedures are described for obtaining plasma with growth factors, the vast majority of these procedures reach a plasma with a medium content of growth factors that have to be used in a
[0025] 1 https://issuu.com/robertohdzvides/docs/platelet-rich plasma.pptx
[0026] immediate since, otherwise, the quality of the plasma decreases in terms of the content of activated growth factors.
[0028] This is how the inventors of the present invention, after extensive and exhaustive experiments, have developed a procedure for obtaining pure growth factors and conserving them in such a way that they can be used later effectively.
[0030] DESCRIPTION OF THE INVENTION
[0032] Therefore, in a first aspect, the present invention refers to a process for obtaining and conserving growth factors of high purity (above 90%) that can be used in cellular bioregeneration processes.
[0034] The process of the present invention consists in that, once a platelet-rich plasma is available, the following steps are carried out:
[0036] a) adding a platelet membrane breaking agent to a platelet-rich plasma to obtain a plasma rich in growth factors;
[0037] b) incubating the plasma rich in growth factors of step a) for 30 to 40 minutes at a temperature between 37 and 40 ° C;
[0038] c) cooling the plasma rich in growth factors of step b) for 5 to 7 minutes to obtain a gel and a supernatant, said supernatant containing growth factors at a concentration greater than% 90;
[0039] d) extracting the supernatant with growth factors from step c);
[0040] e) freeze the supernatant with growth factors from step d) at a temperature between -40 ° C and -18 ° C.
[0042] The supernatant obtained in step c) does not contain platelet remains.
[0044] The process of the present invention is preferably carried out in a sterile environment, optionally in a laminar flow hood.
[0046] In stage a), the platelet membrane breaking agent is in charge of releasing the growth factors, optionally the platelet membrane breaking agent. platelets is sodium gluconate in solution, preferably with a concentration between 100 mg / mL. Preferably, the solution is added to the platelet-rich plasma at 20% v / v.
[0048] The growth factors (without platelet residues) obtained by the process of the present invention have been shown to be more effective when used in bioregeneration processes compared to the performance of other forms of plasma derivatives such as platelet-rich plastics, PRGF and PRGF activated. By using the growth factors of the present invention, a greater effect is achieved with lower doses of product and fewer applications, which demonstrates better assimilation by the patient.
[0050] Additionally, the product is stored for up to 18 months and shows to maintain its effectiveness in terms of growth factor content. The product does not show loss of effectiveness when defrosted up to three times.
[0052] EXAMPLES
[0054] For a better understanding and in a non-limiting manner, the present invention is described in more detail in the embodiments and tests described below.
[0056] Example 1. Obtaining and conserving pure growth factors Inside a laminar flow hood, in a 6 milliliter Vacutainer tube, 1 milliliters of PRP were deposited with 0.2 milliliters of sodium gluconate in solution (with a concentration of 100 mg / ml).
[0058] The tube was incubated for 30 minutes at 40 ° C. Then it was fan cooled for 5 minutes. This process was carried out in an ISM Equipment)
[0060] A gel and a supernatant were obtained with the growth factors. The tube was inverted and with the help of a syringe the supernatant was extracted until the gel was very reduced.
[0062] Because the supernatant containing the pure growth factors loses very rapidly its activity at room temperature, the material is deposited rapidly (in a time significantly less than 5 minutes) in sterile vials.
[0064] Prior to use, the vials are subjected to a bacteriological control to guarantee their sterility.
[0066] The sterile vials are then frozen at -18 ° C and, in some cases, at -40 ° C using dry ice.

权利要求:
Claims (4)
[1]
1. Procedure for obtaining pure growth factors, characterized in that it comprises the stages of:
to. adding a platelet membrane breaking agent to a platelet-rich plasma, to obtain a plasma rich in growth factors;
b. incubating said plasma rich in growth factors of step a) for 30 to 40 minutes at a temperature between 37 and 40 ° C;
c. cooling the plasma rich in growth factors of step b) for 5 to 7 minutes to obtain a gel and a supernatant, in which said supernatant contains growth factors at a concentration greater than 90%;
d. extracting the supernatant with growth factors from step c);
and. deep-freeze the supernatant with growth factors from step d) at a temperature between -40 ° C and -18 ° C.
[2]
The method of claim 1, characterized in that the platelet membrane breaking agent is sodium gluconate in solution.
[3]
3. The method of claim 2, characterized in that the sodium gluconate in solution has a concentration of 100 mg / mL and is added to the platelet-rich plasma at 20% v / v.
[4]
4. The method of any of the preceding claims, characterized in that it is performed in a sterile environment.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US7811558B2|2010-10-12|Use of stabilized platelets as hemostatic agent

---

ES2524549T3|2014-12-10|Procedures and compositions for vein extraction and autotransplantation

---

BR112012009560B1|2021-03-09|composition production method to induce tissue regeneration through activation of platelet-rich plasma | and composition

---

JP2018164757A5|2018-12-06|

---

ES2639561T3|2017-10-27|Procedure for preparing a growth factor concentrate derived from human platelets

---

Anitua et al.2014|The type of platelet-rich plasma may influence the safety of the approach

---

RU2624214C1|2017-07-03|Method for cryopreservation of haemopoietic stem cells

---

RU2506946C1|2014-02-20|Technique of platelet-rich plasma lyophilisation with preserving tgf pdgf vegf factor viability

---

Hosny et al.2015|Assessment of vascular endothelial growth factor in fresh versus frozen platelet rich plasma

---

US8734854B2|2014-05-27|Process for removing growth factors from platelets

---

Tashnizi et al.2013|Treatment of non-healing sternum wound after open-heart surgery with allogenic platelet-rich plasma and fibrin glue-preliminary outcomes

---

RU2589648C2|2016-07-10|Method and apparatus for producing serum with thrombin from one donor

---

ES2782723B2|2021-05-18|PROCEDURE FOR OBTAINING AND CONSERVING HIGH PURITY GROWTH FACTORS AND THEIR USES

---

CN107427535A|2017-12-01|Blood clot through modification

---

RU2631642C1|2017-09-25|Method for treating nonscarring alopecia

---

RU2704489C1|2019-10-29|Method for production of cell-free matrix of derma for further reconstruction of extensive defects of soft tissues

---

RU2710367C2|2019-12-26|Method for producing cytokines from umbilical blood thrombocytes as substrate for developing drugs for humans and animals

---

Shi et al.2019|Effects of a protective agent on freeze-dried platelet-rich plasma

---

Malinin1966|Processing and storage of viable human tissues

---

ES2393192T3|2012-12-19|Blend messenger enhancer of wound healing

---

RU2638796C1|2017-12-15|Method for obtaining of two-component preparation for treatment of joints damage by low-invasive introduction into joint bag and preparation obtained by this method

---

Oseni et al.2013|Rapid production of autologous fibrin hydrogels for cellular encapsulation in organ regeneration

---

Özgürtaş et al.2016|Platelet-rich plasma

---

RU2230454C2|2004-06-20|Cold-safety solution for freezing platelets at moderately low temperature

---

RU2691323C1|2019-06-11|Method of treating bronchial fistulas caused by resection of lungs

同族专利:

---

公开号 | 公开日

---

CO2021011806A2|2021-09-30|

---

WO2020183051A1|2020-09-17|

---

EP3939600A1|2022-01-19|

---

ES2782723B2|2021-05-18|

---

CN113573718A|2021-10-29|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

WO2014126931A1|2013-02-15|2014-08-21|Victor Steven|Stable platelet- rich-plasma compositions and methods of use|

---

ES2527967A2|2013-08-01|2015-02-02|Biotechnology Institute, I Mas D, S.L.|Formulation of a blood composition rich in platelets and/or growth factors, with gel-type proteins, and method for the preparation thereof|

---

AR022333A1|1999-01-26|2002-09-04|Anitua Aldecoa Eduardo|OSEO FABRIC REGENERATOR|

---

ES2221770B2|2002-04-19|2006-07-16|Eduardo Anitua Aldecoa|METHOD OF PREPARATION OF A COMPOUND FOR THE REGENERATION OF FABRICS.|

---

ES2273574B1|2005-06-01|2008-04-01|Maria Jesus Vicente Lobera|METHOD FOR THE PREPARATION OF SOILS OR AUTOMATIC PLASMS RICH IN GROWTH FACTORS.|

---

US9164079B2|2011-03-17|2015-10-20|Greyledge Technologies Llc|Systems for autologous biological therapeutics|

---

法律状态:
2020-09-15| BA2A| Patent application published|Ref document number: 2782723 Country of ref document: ES Kind code of ref document: A1 Effective date: 20200915 |

---

2021-05-18| FG2A| Definitive protection|Ref document number: 2782723 Country of ref document: ES Kind code of ref document: B2 Effective date: 20210518 |

优先权:

---

申请号 | 申请日 | 专利标题

---

ES201930230A|ES2782723B2|2019-03-13|2019-03-13|PROCEDURE FOR OBTAINING AND CONSERVING HIGH PURITY GROWTH FACTORS AND THEIR USES|ES201930230A| ES2782723B2|2019-03-13|2019-03-13|PROCEDURE FOR OBTAINING AND CONSERVING HIGH PURITY GROWTH FACTORS AND THEIR USES|

---

CN202080020363.5A| CN113573718A|2019-03-13|2020-03-12|Method for obtaining and preserving high purity growth factors and uses thereof|

---

EP20769730.1A| EP3939600A1|2019-03-13|2020-03-12|Method for obtaining and preserving high-purity growth factors and uses thereof|

---

PCT/ES2020/070176| WO2020183051A1|2019-03-13|2020-03-12|Method for obtaining and preserving high-purity growth factors and uses thereof|

---

CONC2021/0011806A| CO2021011806A2|2019-03-13|2021-09-08|Procedure for obtaining and conserving high purity growth factors and their uses|